What can you do if you’re a biopharmaceutical company whose top-selling drug is seeing rapidly declining sales? You go on a buying spree—or at least, that’s what this top biotech is doing. Here’s why the results for shareholders are set to be fantastic. More than a third of AbbVie’s (ABBV) 2022 revenue came from Humira, […]
Biotech
Pharma Giant Prioritizing Shareholder Dividends
A good hunting ground for dividend stocks is often companies from which Wall Street wants to see strong performance in the short-term, while its long-term prospects are actually what are most bright. One such case is this pharmaceutical giant, whose management has chosen to prioritize the dividend, despite an uncertain short-term outlook… The company in […]
The Weight Loss Drug Gold Mine
On September 27, the healthcare data analytics firm Trilliant Health released a blockbuster report on the volume of prescriptions for GLP-1 weight loss drugs. The report said that prescriptions for drugs like Ozempic—approved by the FDA in 2017 to treat patients with type 2 diabetes—and Wegovy (for weight loss) increased 300% from the start of […]
Live off the Fat of the Land With These Two Stocks
The Merriam-Webster dictionary defines the idiom “to live off the fat of the land” this way: “to live very well by enjoying the best things that are available without having to work hard to get those things.” Investors can do this literally and sit back and watch their money grow, without doing much work, by […]
Buy This Pharma Powerhouse With a 4% Yield
Imagine a company whose stock that hit an all-time in December 2021, after soaring 50% that year. And that company’s sales doubled in the two years leading up to 2022. And its operating profits quadrupled. Also imagine a company whose biggest product is set to see its sales collapse in the next three years from […]
This Boring Stock Will Be a Winner in 2023
I continue to maintain that the 2023 stock market will look a lot like the 2022 stock market. Big tech continues to reel from overspending during the pandemic, and are being forced to fire large numbers of employees to cut costs. Meanwhile, America’s more traditional mid-cap companies in dull sectors like manufacturing—which have had to […]
Fatten Your Portfolio with Diabetes Treatments
As the emerging world’s economies grow and become more developed, healthcare professionals are worried about an unpleasant side effect. Whenever populations’ dietary habits change amid economic growth, more and more people are become overweight. This, in turn, leads to a dramatic rise in cases of diabetes. But there’s hope on the horizon for those suffering […]
AstraZeneca’s Next “Wonder Drug”
My favorite among the major pharmaceutical companies remains AstraZeneca (AZN). One of the main reasons is that the company specializes in one of the areas where personalized medicine is making the greatest strides: oncology, in which AstraZeneca is the recognized leader. AstraZeneca already has three blockbuster oncology drugs. Here’s what Morningstar said about these drugs […]
The Viral “Tripledemic” Opportunity
Scientists began warning of a potential “twindemic” – a simultaneous surge in both Covid-19 and flu cases – in the autumn. Add in the respiratory syncytial virus (RSV) into the mix and you have the United States in the throes of a viral “tripledemic”. In early December, the U.S. Centers for Disease Control and Prevention […]
What’s Next for mRNA Vaccine Makers
Before the coronavirus pandemic, most of us had never heard of mRNA vaccines, which is not surprising. Although scientists had been experimenting with the technology for literally decades (reminiscent of fusion), the technology had never progressed beyond the laboratory and into widespread medical use. But now, many of us have been vaccinated against COVID-19 with […]